RTI uses cookies to offer you the best experience online. By and clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Accept
  • Home
  • Impact
  • Publications
  • Direct costs to private insurers of diversion of medications for attention-deficit/hyperactivity disorder

Direct costs to private insurers of diversion of medications for attention-deficit/hyperactivity disorder

Aldridge, A., Kroutil, L., Cowell, A., Reeves, D., & Van Brunt, D. (2011). Direct costs to private insurers of diversion of medications for attention-deficit/hyperactivity disorder. PharmacoEconomics, 29(7)(1170-7690), 621 - 635.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Is necessity also the mother of implementation? COVID-19 and the implementation of evidence-based treatments for opioid use disorders
Article

Aplnr knockout mice display sex-specific changes in conditioned fear
Article

The effectiveness of mHealth and eHealth tools in improving provider knowledge, confidence, and behaviors related to cancer detection, treatment, and survivorship care
Article

Increasing the resolution and precision of psychiatric genome-wide association studies by re-imputing summary statistics using a large, diverse reference panel